We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The company plans to use the funds for team expansion in India, geographical footprint in other South Asian countries, and invest in clinical trials for their novel in-licensed assets
Sayre Therapeutics will be able to distribute, market and sell LUTRATE Depot in one and three month formulations for India, Sri Lanka, Bangladesh and Nepal